| Literature DB >> 30859279 |
K Riedmann1, F Bassermann2,3, P J Jost1,4.
Abstract
Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various tyrosine kinases efficiently but not specifically, they are often characterized by their versatile use in a wide variety of entities and diseases. The diverse use of this group of drugs, as well as the challenge of their side-effect profile, continues to make kinase inhibitors the subject of numerous clinical studies. The following article provides an overview of recent new approvals in the field of kinase inhibitors and shows their importance for oncological therapy.Entities:
Keywords: Carcinoma, non-small-cell lung; Leukemia, myeloid; Molecular targeted therapy; Protein kinase inhibitors, adverse effects; Protein-tyrosine kinases
Mesh:
Substances:
Year: 2019 PMID: 30859279 DOI: 10.1007/s00108-019-0577-8
Source DB: PubMed Journal: Internist (Berl) ISSN: 0020-9554 Impact factor: 0.743